title: Results of the MRC myelomatosis trials for patients entered since 1980.
authors.forename: I C
authors.initials: IC
authors.lastname: MacLennan
authors.forename: K
authors.initials: K
authors.lastname: Kelly
authors.forename: R A
authors.initials: RA
authors.lastname: Crockson
authors.forename: E H
authors.initials: EH
authors.lastname: Cooper
authors.forename: J
authors.initials: J
authors.lastname: Cuzick
authors.forename: C
authors.initials: C
authors.lastname: Chapman
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D011897:Random Allocation; D006113:United Kingdom
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine